BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Voronoi\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Voronoi\, Inc's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05315700-2662@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enozertinib: Phase 1/2 readout est. (NCT05315700)
DESCRIPTION:Enozertinib\, phase 1/2.\nStudy: Study of ORIC-114 in Patients 
 With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/enozertinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05315700
URL:https://assetmemo.bio/drug/enozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699328-2801@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:VRN110755: Phase 1/2 readout est. (NCT07699328)
DESCRIPTION:VRN110755\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer\
 nEstimated primary completion: 1 January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/vrn110755#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07699328
URL:https://assetmemo.bio/drug/vrn110755#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
